Sanofi-Aventis has filed suit against Wockhardt alleging that the Indian generics maker has infringed the Orange book listed patents for Sanofi prostate treatment Uroxatral (Alfuzosin) Extended release 10 mg tablets.
Alfuzosin hydrochloride is an alpha-adrenergic blocker used to treat benign prostatic hyperplasia (BPH). It works by relaxing the muscles in the prostate and bladder neck, making it easier to urinate. Alfuzosin was approved by the FDA for treatment of BPH in June 2003. The following are Orange book listed patents for (Alfuzosin) Extended release 10 mg tablets.
US4661491 (Expiry: JAN 18, 2011)- Method of use for the treatment of dysuria
US6149940 (Expiry: AUG 22, 2017)- Controlled release Tablet
Alfuzosin hydrochloride is an alpha-adrenergic blocker used to treat benign prostatic hyperplasia (BPH). It works by relaxing the muscles in the prostate and bladder neck, making it easier to urinate. Alfuzosin was approved by the FDA for treatment of BPH in June 2003. The following are Orange book listed patents for (Alfuzosin) Extended release 10 mg tablets.
US4661491 (Expiry: JAN 18, 2011)- Method of use for the treatment of dysuria
US6149940 (Expiry: AUG 22, 2017)- Controlled release Tablet
Sanofi-Aventis has earlier sued 10 generic players like Actavis, Aurobindo, Barr Laboratories, Mylan, Par, Ranbaxy, Sun, Teva, Torrent and Apotexfor filing Para IV against orange book listed patents.
